三种胰酶抑制药治疗急性胰腺炎成本-效果分析

Cost-effectiveness Analysis of Three Kinds of Pancreatin Inhibitors in the Treatment of Acute Pancreatitis

目的 :对急性胰腺炎 3种胰酶抑制药治疗方案进行成本 效果分析。方法 :回顾调查 67例急性胰腺炎患者 ,按不同治疗药物分为乌司他丁组、善得定组、施他宁组 ,运用药物经济学方法进行成本 效果分析评价。结果 :三组治疗效果差异无显著性 ,但施他宁组的治疗费用远高于乌司他丁组、善得定组 ,乌司他丁组最低。结论 :乌司他丁系国产制剂 ,来源方便 ,治疗费用低 ,可作为治疗急性胰腺炎的首选药物。

Objective:To evaluate the cost effectiveness of three kinds of pancreatin inhibitors in the treatment of acute pancreatitis. Methods:67 patients with AP were divided into three groups according to the therapy drug:ulinastatin group(20 patients), sandostatin group(22 patients), and stilanin group(25 patients). The cost effectiveness of the three kinds of pancreatin inhibitors were evaluated by the pharmacoeconomics method. Results:There is no significant difference in clinical efficacy indexes among the three groups. But the cost of the stilanin group is much higher than the other groups, and the cost of ulinastatin group is the lowest. Conclusion:Ulinastatin is the drug of first choice in the treatment of acute pancreatitis.